- Home
- ABL vs WVE Comparison
ABL vs WVE Comparison
Compare ABL & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- WVE
- Stock Information
- Founded
- ABL 2004
- WVE 2012
- Country
- ABL United States
- WVE Singapore
- Employees
- ABL N/A
- WVE N/A
- Industry
- ABL Investment Managers
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- WVE Health Care
- Exchange
- ABL Nasdaq
- WVE Nasdaq
- Market Cap
- ABL 853.6M
- WVE 984.9M
- IPO Year
- ABL N/A
- WVE 2015
- Fundamental
- Price
- ABL $7.73
- WVE $6.01
- Analyst Decision
- ABL Strong Buy
- WVE Strong Buy
- Analyst Count
- ABL 4
- WVE 11
- Target Price
- ABL $13.63
- WVE $20.91
- AVG Volume (30 Days)
- ABL 453.4K
- WVE 1.5M
- Earning Date
- ABL 05-08-2025
- WVE 05-08-2025
- Dividend Yield
- ABL N/A
- WVE N/A
- EPS Growth
- ABL N/A
- WVE N/A
- EPS
- ABL N/A
- WVE N/A
- Revenue
- ABL $134,575,948.00
- WVE $104,939,000.00
- Revenue This Year
- ABL $65.34
- WVE N/A
- Revenue Next Year
- ABL $25.72
- WVE N/A
- P/E Ratio
- ABL N/A
- WVE N/A
- Revenue Growth
- ABL 73.39
- WVE N/A
- 52 Week Low
- ABL $6.34
- WVE $4.25
- 52 Week High
- ABL $12.40
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- ABL 34.93
- WVE 39.86
- Support Level
- ABL $7.90
- WVE $5.89
- Resistance Level
- ABL $8.50
- WVE $6.30
- Average True Range (ATR)
- ABL 0.28
- WVE 0.32
- MACD
- ABL -0.15
- WVE 0.01
- Stochastic Oscillator
- ABL 9.49
- WVE 10.17
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.